The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s G-CSF (granulocyte colony stimulating factors) market report forecasts the G-CSF (granulocyte colony stimulating factors) market size to grow to $9.94 Billion by 2027, with a CAGR (compound annual growth rate) of more than 4%.

Learn More On The G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2023 – https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

G-CSF (Granulocyte Colony Stimulating Factors) Market Size Forecast
The global G-CSF (granulocyte colony stimulating factors) market is expected to grow from $7.99 billion in 2022 to $8.43 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The G-CSF (granulocyte colony stimulating factors) market is expected to grow from $9.94 billion in 2027 at a CAGR of 4.2%.

Key G-CSF (Granulocyte Colony Stimulating Factors) Market Driver ­– Increase In Demand For Prophylaxis Granulocyte Colony-Stimulating Factor
The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN), allowing patients to receive and stay on myelosuppressive chemotherapy. Over the next ten years, current G-CSF prophylaxis offers significant benefits, including a reduction in febrile neutropenia of 3.3 million cases and a reduction in chemotherapeutic dosage intensity of less than 85%. Therefore, the increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is expected to drive the growth of the granulocyte-colony stimulating factor market.

Request for A Sample Of The Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

G-CSF (Granulocyte Colony Stimulating Factors) Market Segment
1) By Type: Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex)
2) By Application: Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic And Autoimmune Disorders, Other Applications
3) By Product: Tablet, Capsule, Other Products

G-CSF (Granulocyte Colony Stimulating Factors) Market Major Players and Strategies
Major players in the G-CSF (granulocyte colony stimulating factors) market are BioCad, Teva Pharmaceuticals, Pfizer, Intas Pharmaceuticals, Novartis AG, StadaArzneimittel, Dong-A Socio Group, Amgen, Dr. Reddy’s Laboratories, and Celltrion Inc.

In December 2021, Novartis AG, a Switzerland-based pharmaceutical company specialising in the discovery, development, manufacturing, and commercialization of medicines, acquired Gyroscope Therapeutics Holdings plc for an amount of $800 million. Through this acquisition, G-CSF drugs would be added to the Novartis portfolio, increasing gene therapy research capabilities and bringing ophthalmic innovation to treat and prevent blindness globally. Gyroscope Therapeutics Holdings plc is a UK-based clinical stage biopharmaceutical company pioneering in the research and development of biosimilars for the treatment of eye related diseases.

The G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2023 covers regional data on G-CSF (granulocyte colony stimulating factors) market size, G-CSF (granulocyte colony stimulating factors) market trends and drivers, opportunities, strategies, and G-CSF (granulocyte colony stimulating factors) market competitor analysis. The countries covered in the G-CSF (granulocyte colony stimulating factors) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

G-CSF (granulocyte colony stimulating factors) refers to a type of colony-stimulating factor that aids in the bone marrow’s ability to produce more white blood cells. Patients who have specific tumours, neutropenia brought on by some types of chemotherapy, or severe persistent neutropenia unrelated to cancer treatment are all treated with G-CSF. Filgrastim and Granulocyte Colony-Stimulating Factor are other names for it.

View More Reports Related To The G-CSF (Granulocyte Colony Stimulating Factors) Market –
Therapeutic Proteins Global Market Report 2023
Hepatitis Drugs Global Market Report 2023
Biosimilars Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: